Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through Exercise: the flADex Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Universidad de Granada
- Enrollment
- 20
- Locations
- 4
- Primary Endpoint
- Change in Cerebral Blood Flow (CBF)
Study Overview
Brief Summary
Dementia is one of the leading causes of disability worldwide. Underlying biological mechanisms are crucial in preclinical stages of Alzheimer's disease (AD). Alterations in cerebral blood flow (CBF) and their relationship with AD blood-based biomarkers may be fundamental at early stages of the pathology. Physical exercise is a trigger to modify these biological mechanisms. Therefore, flADex aims to examine the acute effects of different types of exercise (resistance vs. aerobic vs. control) on CBF, AD blood-based biomarkers, and its cognitive implications in older adults. The hypothesis is that acute resistance or aerobic exercise will fluctuate levels of blood-based biomarkers, and will exert acute CBF changes combined with cognitive implications.
Detailed Description
The aging population is at an increasing risk of developing Alzheimer's Disease (AD), which is characterized by cognitive decline and memory loss. Current pharmacological treatments have targeted amyloid-beta (Aβ) and tau protein, and have largely failed to halt or reverse the progression of AD. This has led to a growing interest on examining additional underlying mechanisms responsible for the initiation of AD pathology in this preclinical stage, such as cerebral blood flow (CBF) alterations or peripheral levels of AD blood-based biomarkers. Parallelly, exercise might act as a trigger for these potential underlying mechanisms of AD in older adults. Thus, this study seeks to explore the acute effects of different type of exercise on CBF, blood-based biomarkers, and its cognitive implications in older adults.
FlADex is a counterbalanced crossover trial that will include 20 adults aged 68 to 83 with non-pathological brain amyloid status (<12 centiloid) and APOE e4 noncarriers. Each participant will be included in all study conditions in a randomized order: (i) moderate aerobic exercise (between 60-70 of the Maximal Heart Rate (HRmax); (ii); resistance exercise (4-6 Moderate intensity of Rate of Perceived Exertion) and (iii) control resting condition. Each condition, lasting 30 minutes, will be performed once. CBF will be assessed by magnetic resonance imaging using pseudo-continuous arterial spin labeling at pre-condition and at 3 consecutive times post-condition (at 20', 27' and 34' min). Blood-based biomarkers (Aβ42, Aβ40, p-tau217, p-tau181, GFAP, NfL, BDNF, IGF-1) will be measured pre-condition and post-condition (at 0', 50', 70' min). Cognitive outcomes (Flanker Test and Picture Sequence Memory Test) and mood status (feeling scale and POMS questionnaire) will be measured pre and post condition.
FlADex trial will shed light on the acute effects of different types of exercises on CBF and AD blood-based biomarkers before beta-amyloid accumulation. We expect that aerobic and resistance exercise will have different effects on CBF dynamics and AD blood biomarker levels over time in older adults
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Basic Science
- Masking
- Double (Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 68 Years to 83 Years (Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Older adults
- •Aged 68-83 years
- •Non-pathological cerebral beta-amyloid status (based on Centiloid cut-point <12 measured by PET-CT)
- •APOEe4 negative status
- •Willingness to participate in exercise interventions
Exclusion Criteria
- •Pathological diagnosis related to physical or mental condition
- •No living in community settings during the study
- •MRI incompatibility
- •Ambulatory with pain or regular use of an assisted walking device
- •Severe cardiovascular or respiratory conditions
- •Participation in another clinical trial within the last 30 days
Outcomes
Primary Outcomes
Change in Cerebral Blood Flow (CBF)
Time Frame: 30 minutes before the experimental condition; and 20 minutes, 27 minutes and 34 minutes minutes after the experimental condition
Specific acquisition parameters for Pseudo continuous Arterial Spin Labeling (pCASL) sequence are used to determinate global and regional CBF in resting condition. Structural T1 sequence (only pre-condition) is used to coregisted the pCASL and delineate regions of interest for CBF. Time-of-flight angiography (TOF) (before pCASL pre-condition and before first pCASL post-condition) sequence is used to identify the carotid arteries. The unit of measurement of the CBF is expressed as milliliters per 100 grams of brain tissue per minute (mL/100 g/min).
Secondary Outcomes
- Change in Alzheimer disease blood-based biomarkers (Aβ42/40 ratio)(5 minutes before the experimental condition; and 0 minutes, 50 minutes and 70 minutes after the experimental condition)
- Change in Alzheimer disease blood-based biomarkers (p-tau217, p-tau181, NfL and GFAP)(5 minutes before the experimental condition; and 0 minutes, 50 minutes and 70 minutes after the experimental condition)
- Change in growth factors (BDNF)(5 minutes before the experimental condition; and 0 minutes, 50 minutes and 70 minutes after the experimental condition)
- Change in growth factors (IGF-1)(5 minutes before the experimental condition; and 0 minutes, 50 minutes and 70 minutes after the experimental condition)
- Change in episodic memory(15 minutes before the experimental condition; and 60 minutes after the experimental condition)
- Change in inhibition/attention(15 minutes before the experimental condition; and 60 minutes after the experimental condition)
- Mood status(POMS will be measured 60 minutes before the experimental condition; and 70 minutes after the experimental condition)
- Feeling scale(Feeling scale will be measured 1 minute before the experimental condition; and 1 minute after the experimental condition)
Investigators
Irene Esteban-Cornejo
Ramon y Cajal Assistant Professor, PhD
Universidad de Granada